Roth Capital maintains Buy on Vicor, raises target to $375
Roth Capital analyst Justin Clare maintained a Buy rating on Vicor and raised the price target to $375 from $285, signaling strong confidence in the company's future performance.
*this image is generated using AI for illustrative purposes only.
Roth Capital analyst Justin Clare has maintained a Buy rating on Vicor and raised the price target to $375 from $285. The revised target reflects increased confidence in the company's performance potential.
The adjustment follows a review of Vicor's market position and financial outlook. The previous target of $285 has been increased significantly to $375, indicating a strong upside from current levels.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $285 |
| New Price Target | $375 |
Vicor continues to be viewed favorably by Roth Capital, with the new target suggesting robust growth expectations.
What specific market trends or product developments drove Roth Capital's increased confidence in Vicor's performance?
How might this price target revision influence other analysts' ratings on Vicor in the near term?
What are the potential risks that could prevent Vicor from reaching the new $375 price target?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
